Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome
NCT02099422 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2014-03-28
Summary
Comparison of two antiplatelet strategies between months 1 and 12 after coronary stenting for ACS. Efficiency and tolerance évaluation
Conditions
- Acute Coronary Syndrome
- Coronary Stenting
- Antiplatelet Therapy
Sponsors & Collaborators
-
Hôpital de la Timone
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2015-01-31
- Completion
- 2016-01-31
Countries
- France
Study Locations
More Related Trials
-
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
NCT01789814 ·Status: COMPLETED ·Phase: PHASE4
-
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization
NCT03953547 ·Status: COMPLETED
-
Short and Optimal Duration of Dual Antiplatelet Therapy Study
NCT01659034 ·Status: COMPLETED ·Phase: PHASE4
-
Platelet Inhibition in the Acute Phase of STEMI
NCT01144819 ·Status: COMPLETED
-
Platelet Function Assessment for Atherothrombotic Patients
NCT00513149 ·Status: UNKNOWN ·Phase: PHASE4
-
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
NCT00774475 ·Status: UNKNOWN ·Phase: PHASE3
-
Platelet Reactivity And Clinical ThrombotIC Events Study
NCT03525145 ·Status: UNKNOWN
-
Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition
NCT00302913 ·Status: COMPLETED ·Phase: NA
-
Platelet Reactivity After Cessation of Clopid in the Setting of Coronary Stent Implantation I: PRACTICE I
NCT00684359 ·Status: COMPLETED
-
Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation
NCT00404053 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01339026 ·Status: TERMINATED ·Phase: PHASE4
-
Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome
NCT01994941 ·Status: COMPLETED ·Phase: PHASE4
-
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
NCT02925923 ·Status: COMPLETED ·Phase: PHASE2
-
Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet
NCT02500290 ·Status: UNKNOWN
-
the Effect Between Platelet Reactivation and Antiplatelet Drugs
NCT02198053 ·Status: UNKNOWN
-
REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary Syndromes (RECLOSE 2 - ACS)
NCT01231035 ·Status: COMPLETED
-
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
NCT02484924 ·Status: COMPLETED
-
Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)
NCT00751491 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)
NCT01701453 ·Status: UNKNOWN ·Phase: NA
-
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
NCT05730114 ·Status: UNKNOWN
-
Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity
NCT02096419 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Significance of Platelet Reactivity on Clopidogrel During Off-pump Coronary Artery Bypass
NCT01959191 ·Status: COMPLETED
-
Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
NCT00404781 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
NCT00385944 ·Status: COMPLETED ·Phase: PHASE2
-
Dual-antiplatelet Therapy Strategies for Elective PCI in a Real-world Setting
NCT05559918 ·Status: RECRUITING